EIR Ventures
Venture capitalStockholm · Seed–Growth · 9 people tracked
Investment thesis
Eir Ventures invests in companies with transformative medical potential that demonstrate excellence in execution and scalability. The firm focuses on Nordic innovation to develop products and therapies that advance global health and improve patient outcomes while delivering strong financial returns.
Source: firm website, verified Jul 21, 2026.
Team · 9 people
from the firm's websiteMolecular biologist with nearly 20 years in venture investment, company building, and executive leadership. Co-founder of multiple academic and pharma spin-outs and partner-level member at Baxalta Ventures and Connecticut Innovations. Has board and operational experience across the US and Europe.
Finance professional with over 30 years in corporate finance, capital markets, and venture capital. Co-founder and CFO of Voyomotive, a connected vehicle platform firm. Co-founding partner at The Column Group venture capital firm and previously worked in investment banking at Goldman Sachs and Nomura Securities.
Physician and scientist who founded and sold a medical technology company (Aerocrine), held partner positions at life science venture capital firms HealthCap and The Column Group, and has been involved in numerous investments and exits. Based in Stockholm with board experience in Nordic and US companies.
PhD in protein chemistry and immunology with broad executive experience in biotech R&D, operations, and clinical development. Founding member of Novo Seeds investment team and early-stage investor for nearly 20 years, having led creation and funding of over 30 companies primarily in the Nordic region.
Medical doctor with PhD in clinical epidemiology from Karolinska Institute. Served as Head of Business Development at healthcare provider Capio and was a management consultant at Boston Consulting Group focusing on MedTech and Pharma.
Physician and lawyer with pharmaceutical industry experience in regional and global leadership roles at Sanofi Genzyme and Y-mAbs, specializing in rare diseases, immunology, and oncology. Also founded a medtech startup company that digitalizes healthcare provider and pharmaceutical interactions.
Professor at Karolinska Institute and Vice Chancellor of Sri Sathya Sai Institute of Higher Learning. Senior scientist specializing in autoimmune diabetes research with focus on biomarkers and immunogenetic factors. Recipient of the Pravasi Bharathiya Samman Award and serves on multiple scientific advisory boards.
Biotechnology entrepreneur with over 30 years in pharmaceutical discovery and development. Co-founder and CEO of Plexxikon (developed Zelboraf for melanoma) and co-founder of Sugen (advanced kinase inhibitors in oncology including Sutent). Also served as VP of Research at Boehringer Mannheim and holds board positions at multiple biotech companies.
Professor at Karolinska Institute and General Secretary of the Nobel Committee. Research focuses on central nervous system development and regenerative medicine, with particular expertise in dopamine neuron mechanisms relevant to Parkinson's disease research.
What they invest in
from 2 of 29 portfolio companiesBiotech ×2Deep Tech ×2AI & Machine Learning ×1Healthtech ×1Medical Devices ×1
Investments · 29 tracked
founders shown can be your intro pathMoleculent develops biological discovery and disease understanding tools for scientists. The company focuses on decoding molecular foundations of biology to advance human health diagnostics and research.
AI & Machine LearningBiotechDeep Tech
Fredrik Roos(CTO & Co-founder)
Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression. The company leverages expertise in mitochondrial biology and drug discovery to create treatments for diseases associated with mitochondrial dysregulation.
BiotechDeep TechHealthtechMedical Devices<UNKNOWN>
Jay Parrish(Chief Executive Officer & Chairman of the Board)Michal Minczuk(Co-Founder)Gabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)
Developer of Supernitro, a first-in-class nitric oxide delivery therapy for pulmonary hypertension prevention and treatment.
Swedish biopharmaceutical company developing novel potassium-competitive acid blockers for faster and more effective treatment of GERD.
Copenhagen-based oncology company developing treatments for acute myeloid leukemia and other cancer types based on University of Copenhagen research.
NASDAQ-listed company based on Lund University research developing galectin-3 targeting therapies for idiopathic pulmonary fibrosis and other fibrotic diseases.
Biotech developing transformative therapies for metabolic and age-related diseases including obesity, type 2 diabetes, osteoporosis and Parkinson's disease.
Enzyme-based topical therapy for hidradenitis suppurativa developed by former Novozymes scientist.
Danish biotech developing non-opioid restorative treatments for chronic pain, hearing loss and sensory neuron disorders.
Stockholm-based life science tools company studying cell-cell interactions using innovative tissue-context approaches.
Mitochondrial biology-focused biotech founded by leading academics in the field, developing novel therapeutics.
Biopharmaceutical company developing specialty and niche products including treatments for rare diseases, with a first product filing for orphan disease indication.
Swedish digital health platform implementing value-based care monitoring for outpatient surgery to improve quality, patient satisfaction and healthcare efficiency.
Collaborative research enterprise developing compounds targeting RNA modifications in cancer cells with metabolic dysfunction.
Company leveraging Cell-Seq discovery platform to identify genetic modifiers for immuno-oncology and rare metabolic diseases.
Gothenburg University spin-out developing first-in-class sortilin inhibitor therapies targeting metastasis and growth of aggressive cancers.
Swedish precision medicine company using proprietary ADAC technology for individualized immunotherapeutic treatments based on genetic tumor profiles.
Frequently asked questions
- What stage does EIR Ventures invest at?
- EIR Ventures invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does EIR Ventures focus on?
- EIR Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is EIR Ventures located?
- EIR Ventures is headquartered in Stockholm, NO.
- Does EIR Ventures lead rounds?
- Yes, EIR Ventures leads investment rounds.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.